b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">\n        <PMID Version="1">29873009</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>09</Month>\n            <Day>03</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>09</Month>\n            <Day>03</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1865-8652</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>35</Volume>\n                    <Issue>6</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>Jun</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Advances in therapy</Title>\n                <ISOAbbreviation>Adv Ther</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>796-808</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-018-0718-9</ELocationID>\n            <Abstract>\n                <AbstractText Label="INTRODUCTION">This was the first exploratory randomized controlled study to compare the efficacy and safety of a preserved tafluprost/timolol fixed combination (TAF/TIM) with a preserved latanoprost/timolol fixed combination (LAT/TIM).</AbstractText>\n                <AbstractText Label="METHODS">This prospective, randomized, open-label study was conducted in Japanese patients with primary open-angle glaucoma, including normal-tension glaucoma or ocular hypertension. Following a 4-week LAT/TIM run-in period, eligible patients entered a 12-week treatment period, during which they received either LAT/TIM or TAF/TIM. The efficacy endpoint was the change in intraocular pressure (IOP) from baseline to week 12 and the safety endpoints included the changes from baseline to week 12 in superficial punctate keratopathy (SPK) score, tear breakup time (TBUT), and hyperemia score, as well as adverse events (AEs). At week 6, ocular symptoms were evaluated using a questionnaire.</AbstractText>\n                <AbstractText Label="RESULTS">In total, 131 patients provided informed consent. Of these, 115 completed the run-in period and were assigned to receive TAF/TIM (n\xe2\x80\x89=\xe2\x80\x8960) or LAT/TIM (n\xe2\x80\x89=\xe2\x80\x8955). At week 12, there were no significant differences between the TAF/TIM and LAT/TIM groups in the change from baseline in trough IOP and IOP at 4-6\xc2\xa0h after instillation. There were no significant differences between the two groups in the change from baseline to week 12 in SPK score, TBUT, and hyperemia score. However, only in the TAF/TIM group, the total SPK score and the inferior cornea SPK score were significantly lower at week 12 compared with baseline. Eye irritation and eye pain were significantly decreased in the TAF/TIM group compared with the LAT/TIM group. Two treatment-related AEs were reported in the TAF/TIM group (3.3%) and none in the LAT/TIM group, while no serious AEs were reported in either group.</AbstractText>\n                <AbstractText Label="CONCLUSION">TAF/TIM is as effective as LAT/TIM in terms of IOP-reducing effect, with fewer ocular symptoms. TAF/TIM was associated with a significant improvement in SPK scores.</AbstractText>\n                <AbstractText Label="TRIAL REGISTRATION">UMIN Clinical Trials Registry Identifier, UMIN000023862.</AbstractText>\n                <AbstractText Label="FUNDING">Santen Pharmaceutical Co., Ltd., Osaka, Japan.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Suzuki</LastName>\n                    <ForeName>Katsuyoshi</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Suzuki Eye Clinic, Yamaguchi, Japan. suzuki_eye@grace.ocn.ne.jp.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Otsuka</LastName>\n                    <ForeName>Naomi</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Santen Pharmaceutical Co., Ltd., Osaka, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hizaki</LastName>\n                    <ForeName>Hiroko</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Santen Pharmaceutical Co., Ltd., Osaka, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hashimoto</LastName>\n                    <ForeName>Masayo</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Santen Pharmaceutical Co., Ltd., Osaka, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kuwayama</LastName>\n                    <ForeName>Yasuaki</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Fukushima Eye Clinic, Osaka, Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <CollectiveName>Tafluprost/Timolol Versus Latanoprost/Timolol (TTVLT) Study Group</CollectiveName>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <DataBankList CompleteYN="Y">\n                <DataBank>\n                    <DataBankName>UMIN-CTR</DataBankName>\n                    <AccessionNumberList>\n                        <AccessionNumber>UMIN000023862</AccessionNumber>\n                    </AccessionNumberList>\n                </DataBank>\n            </DataBankList>\n            <PublicationTypeList>\n                <PublicationType UI="D003160">Comparative Study</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016448">Multicenter Study</PublicationType>\n                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>06</Month>\n                <Day>05</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Adv Ther</MedlineTA>\n            <NlmUniqueID>8611864</NlmUniqueID>\n            <ISSNLinking>0741-238X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011460">Prostaglandins F</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011461">Prostaglandins F, Synthetic</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>6Z5B6HVF6O</RegistryNumber>\n                <NameOfSubstance UI="D000077338">Latanoprost</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>817W3C6175</RegistryNumber>\n                <NameOfSubstance UI="D013999">Timolol</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>T</CitationSubset>\n        <CommentsCorrectionsList>\n            <CommentsCorrections RefType="ErratumIn">\n                <RefSource>Adv Ther. 2019 Feb;36(2):492-494</RefSource>\n                <PMID Version="1">30617814</PMID>\n            </CommentsCorrections>\n        </CommentsCorrectionsList>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005902" MajorTopicYN="N">Glaucoma, Open-Angle</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007429" MajorTopicYN="N">Intraocular Pressure</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077338" MajorTopicYN="N">Latanoprost</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D057066" MajorTopicYN="N">Low Tension Glaucoma</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009798" MajorTopicYN="N">Ocular Hypertension</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011460" MajorTopicYN="N">Prostaglandins F</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011461" MajorTopicYN="N">Prostaglandins F, Synthetic</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013999" MajorTopicYN="N">Timolol</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014065" MajorTopicYN="N">Tonometry, Ocular</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Beta-blocker</Keyword>\n            <Keyword MajorTopicYN="Y">Efficacy</Keyword>\n            <Keyword MajorTopicYN="Y">Intraocular pressure</Keyword>\n            <Keyword MajorTopicYN="Y">Latanoprost</Keyword>\n            <Keyword MajorTopicYN="Y">Ocular hypertension</Keyword>\n            <Keyword MajorTopicYN="Y">Ophthalmology</Keyword>\n            <Keyword MajorTopicYN="Y">Primary open-angle glaucoma</Keyword>\n            <Keyword MajorTopicYN="Y">Prostaglandin</Keyword>\n            <Keyword MajorTopicYN="Y">Safety</Keyword>\n            <Keyword MajorTopicYN="Y">Tafluprost</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>04</Month>\n                <Day>03</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>6</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>9</Month>\n                <Day>4</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>6</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29873009</ArticleId>\n            <ArticleId IdType="doi">10.1007/s12325-018-0718-9</ArticleId>\n            <ArticleId IdType="pii">10.1007/s12325-018-0718-9</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'